Using the IWG-MRT consensus criteria, we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase II trials: 44 received single-agent thalidomide; 41 single-agent lenalidomide; and 40 a combination of lenalidomide+prednisone. Thalidomide group included significantly
more untreated patients and patients with performance status of 2. Lenalidomide-based therapy produced higher efficacy (34-38%) than thalidomide (16%; p=0.06). Responses to thalidomide were seen within 3-15 weeks, while responses to lenalidomide-based therapy were also seen after prolonged course of therapy (range 2-45 weeks).
Lenalidomide+prednisone therapy resulted in significantly longer response duration (median 34 months) than single-agent lenalidomide or thalidomide (median 7 and 13 months, respectively; p=0.042). Fewer patients (p=0.001) discontinued lenalidomide+prednisone therapy (13%) due to side effects then patients on singleagents therapy (32-39%). In conclusion, the combination of lenalidomide+prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.
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INTRODUCTION
Myelofibrosis (MF) is a clonal stem-cell disorder characterized by intense bone marrow stromal reaction resulting in collagen fibrosis, osteosclerosis, and angiogenesis thought to be mediated in large part by high levels of proinflammatory, fibrogenic and angiogenic cytokines. 1 Thalidomide and lenalidomide are two immunomodulatory agents (IMiDs) with clinical activity in a subset of patients with MF, including improvements in anemia, thrombocytopenia and splenomegaly, thought to be due to their effect on bone marrow environment. [2] [3] In 2006, International Working Group (IWG)
for Myelofibrosis Treatment and Research proposed consensus criteria for evaluation of treatment response in patients with MF. 4 Although now in widespread use, IWG criteria have not been used in previous trials of single agent thalidomide and lenalidomide in MF. Here we report the efficacy and long-term outcome of patients with MF treated with thalidomide or lenalidomide+/-prednisone in three consecutive trials conducted at our institution between 2000 and 2007, as assessed by the IWG response criteria.
PATIENTS and METHODS
A total of 125 patients with MF participated in 3 consecutive Phase II trials with IMiDs after signing informed consent, in accordance with the Declaration of Helsinki, with approval from the Institution Review Board of MD Anderson Cancer Center: 1) 44 received thalidomide at an initial dose of 200mg daily with weekly escalation by 200mg, as tolerated, up to 800mg daily; 2 2) 41 received lenalidomide 10mg/day continuously (5mg/day if pretherapy platelets <100 x10 9 /L); 3 3) 40 received lenalidomide 10mg/day (5mg/d if pretherapy platelets <100 x10 9 /L) on days 1-21 of 28-day cycles, in For personal use only. on October 22, 2017. by guest www.bloodjournal.org From combination with prednisone that was given for only 3 cycles: 30mg/day during cycle 1, 15mg/d during cycle 2, and 15mg/d every other day during cycle 3. 5 No deep venous thrombosis prophylaxis agent was administered. Responders continued treatment until loss of the response or a development of intolerance. Responses were assessed using the IWG criteria and response rates calculated based on intent-to-treat analysis.
Eligibility criteria were similar for the 3 study groups. Differences among variables were evaluated by the chi-square test and Mann-Whitney U test for categorical and continuous variables, respectively. Toxicity was assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.
RESULTS and DISCUSSION
Among patients' characteristics (Table 1A) Of the 41 patients treated with single-agent lenalidomide, 14 (34%) responded: 2 (5%) CR, 5 (12%) PR, and 7 (17%) CI. The median duration of response was 7 months. The
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From median duration of the CI was 12 months (range 2-36) with 4 patients becoming transfusion independent. After a median follow-up of 42 months, 15 of the 40 patients (38%) treated with lenalidomide+prednisone combination responded: 2 (5%) CR, 4 (10%) PR, and 9 (23%) CI, with the median duration of a response of 34 months (range 1-49+). One patient converted his response from PR to CR recently after more than 10 cycles of therapy. The median duration of CI was 7 months (range 1-33+) with 4 becoming transfusion independent. Six patients still remain on the study with 2 CR, 3 PR, and 1 stable disease.
There was a trend for a higher efficacy in patients receiving lenalidomide-based therapy (p=0.06; Table 1B ). Lenalidomide-based therapy had higher efficacy on reducing the spleen size than thalidomide. In a multivariate analysis conducted for response, lenalidomide based regimen was the only factor independently associated with higher response rate. Response to thalidomide was seen after 8 weeks (range 3-15 weeks) but not later, while responses to lenalidomide+/-prednisone were seen also after prolonged course of therapy (up to 45 weeks) leading to significant differences in the median time to first and best response (Table 1B; Figure 1A ). Patients in lenalidomide+prednisone group had responses of significantly longer duration then patients in single agent groups, with ongoing median response duration of 34 months ( Figure 1B ). There was no survival difference between the 3 groups of patients, partly due to sequential therapies administered where patients who failed thalidomide received salvage therapies (p=0.129). Fourteen patients who failed thalidomide received subsequent lenalidomide-based therapy. Eight responded: 5/11 patients The most common thalidomide side effects were neuropathy, rash, and fatigue, as previously reported. 2 In the lenalidomide single-agent group fatigue was also commonly reported, but not in the lenalidomide+prednisone group, likely due to prednisone use. Interestingly, rash was seen in lenalidomide+prednisone group later in the course of therapy when patients were off prednisone. Most non-hematologic side effects observed were of Grade 1 and 2 (Table 1C ). Lenalidomide-based therapy caused more myelosuppression than thalidomide (Table 1D) , as expected from previous experience. 3 Contrary to the experience in multiple myeloma, 6 the combination of lenalidomide and prednisone did not induce a higher rate of thrombotic events.
Overall, significantly fewer patients (p=0.001) discontinued lenalidomide+prednisone therapy (13%) due to side effects then patients on single agent thalidomide (39%) or lenalidomide (32%).
We and others have previously reported objective clinical responses in MF to thalidomide and lenalidomide single-agent therapy of up to 60%. 2-3 However, different studies employed different response criteria and therefore IWG established a set of clinically relevant response criteria several years ago, 4 now utilized in almost all MF studies. Re-assessing our experience with IMiDs in MF we found the combination of lenalidomide+prednisone to be possibly more effective (particularly important aspect is significantly longer response duration) and safer than single-agent thalidomide or lenalidomide. This could be explained in part by a better non-hematologic safety profile leading to less treatment withdrawal due to toxicity in lenalidomide+prednisone group, For personal use only. on October 22, 2017. by guest www.bloodjournal.org From but also by the potential therapeutic synergy of lenalidomide and prednisone. 5, 7 Corticosteroid therapy alone has shown a response rate in anemia (CI in anemia by IWG criteria) in 19% of MF patients. 8 The antiangiogenic, proapoptotic, and immunomodulatory effects of IMiD might be enhanced by the addition of prednisone to suppress inflammatory stimuli, reduce marrow fibrosis, and improve cytopenias. 3, 5 Three aspects of our results require discussion. First, low dose (50mg) thalidomide+prednisone is an alternative regimen that may be better tolerated by MF patients and result in fewer patients discontinuing therapy due to toxicity, resulting in better efficacy (up to 30% by IWG). 9 However, the duration of response may not be longer than in our experience (median 8.5 months). 9 Second, responses to lenalidomide+prednisone may occur after prolonged period of therapy and may improve over time. 7 Continuous therapy is mandatory to achieve significant and durable responses. Recent multi-center study of lenalidomide+prednisone in 42 MF patients resulted in 23% IWG response rate; however, only 25 patients received up to 6 cycles of therapy, and therapy was then stopped. 10 Third, despite the fact that the inclusion criteria and patient characteristics were similar in our three consecutive trials, the design of the trials does not allow strict comparisons. However, our analysis using the IWG-
MRT consensus criteria of response identified the expected responses observed with
IMiDs in MF; that may allow some degree of comparison with future novel MF therapies such as pegylated form of interferon and Jak-2 inhibitors. 
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